European Primary Care Cardiovascular Society

Lipids

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

After stopping therapy, continued benefit of statin treatment

5' education - July 12, 2021 - Jackie Bosch, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

New cholesterol guidelines: aim therapy at patients at highest risk who will benefit most

3' education - Nov. 22, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Lipids and food

10' education - July 11, 2018 - Prof. David Marais - Cape Town, South Africa

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

How do the latest guideline changes affect management of dyslipidaemia in primary care?

10' education - May 26, 2017

What is the evidence base for lipid modification in the guidelines updates?

10' education - Feb. 24, 2016 - Prague - EPCCS 2015

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Cholesterol guideline breaking news in USA

3' education - Dec. 16, 2013 - AHA 2013 - Clyde Yancy

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in  patients who are already being treated with statins.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD
A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we going to be able to treat this disorder”, Nissen said.

ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.

A meta-analyis on the worldwide prevalence of statin intolerance

Literature - Feb. 28, 2022 - Bytyçi I, et al. - Eur Heart J 2022

A meta-analysis including data of >4 million patients showed that the prevalence of statin intolerance (SI) is as low as 9.1% and independent of the international definitions.

Online self-assessment for nonprescription statin therapy

Literature - Jan. 4, 2022 - Nissen SE et al. - J Am Coll Cardiol. 2021

A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.

Cost-effectiveness of a population genomic screening strategy for familial hypercholesterolemia

Literature - Dec. 14, 2021 - Marquina C et al. - Eur Heart J. 2021

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

Lipid lowering therapy use in high and very high CV risk patients in Europe

News - Oct. 5, 2021

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

Agreement by NHS on population health management approach using PCSK9 siRNA therapy

News - Sep. 15, 2021

The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.

A debate at ESC Congress: Benefit from omega-3 fatty acids?

News - Sep. 15, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

FH is diagnosed late and poorly managed shown in global registry study

Literature - Sep. 15, 2021 - EAS Familial Hypercholesterolaemia Studies Collaboration (FHCS) - The Lancet 2021

The EAS FHSC have created a global registry of FH patients for the surveillance of FH worldwide. Findings of the present study on the adult population show that FH is diagnosed late and LDL-c targets are often not achieved.

Clinical inertia in patients with FH and CVD

Literature - Aug. 9, 2021 - Langer A et al. - J Am Heart Assoc. 2021

Physician reminders for recommended LLT led to an increase in the proportion of patients with FH and/or CVD achieving LDL-c treatment goals. However, treatment inertia exists in patients with FH, including those with established CVD.

After stopping therapy, continued benefit of statin treatment

5' education - July 12, 2021 - Jackie Bosch, PhD
Jackie Bosch presents the results of the HOPE-3 study that show that CV benefits of statin treatment continued for at least three more years after stopping medication in individuals at intermediate risk for CV events.

Jackie Bosch presents the results of the HOPE-3 study that show that CV benefits of statin treatment continued for at least three more years after stopping medication in individuals at intermediate risk for CV events.